Scientific Industries Inc (OTCPK:SCND)

Q2 2024 Scientific Industries Inc Earnings Call Transcript

Aug 15, 2024 / 03:00PM GMT

Release Date Price: $1.5

Transcript 10-Q

Key Points

Positve

The Genie lab products have shown resilience in revenue, returning to pre-Covid levels despite challenges.
The Torbal pharmacy scale business is experiencing rapid growth and market share gains after a difficult first half of the year.
The launch of the VIVID workstation is expected to accelerate growth in the automated pill counter market.
The bioprocessing segment saw a 16% increase in sales compared to last year, with strong growth in the US market.
Cost management efficiency programs have generated significant savings, improving EBITDA by roughly 20% compared to last year.

Negative

The Genie lab products faced a collapse in demand from Chinese distributors and competition from knockoff products.
The Torbal pharmacy scale business was negatively impacted by changes in billing and reimbursement by pharmacy benefit managers.
The bioprocessing segment experienced weaker demand in Europe and Asia, affecting overall performance.
The company had to implement a voluntary salary waiver program to manage costs, indicating financial strain.
The bioprocessing segment's sales were slightly softer than expected, despite the overall increase.

Operator

Good day, and welcome to the Scientific Industries reports second-quarter year 2024 financial results conference call. (Operator Instructions) Please note, this event is being recorded.

I would now like to turn the conference over to Joe Dorame. Please go ahead.

Joe Dorame

Lytham Partners LLC - Investor Relations

Thanks, Nick. Good morning, and thank you all for joining us today to review Scientific Industries' financial results for the second quarter of 2024 ended June 30, 2024. With us today on the call are Helena Santos, Chief Executive Officer; Daniel Donadille, CEO of Scientific Bioprocessing; and John Moore, Chairman. After the conclusion of today's prepared remarks, we will open the call for questions.

Before we begin with prepared remarks, I would like to remind everyone certain statements made by the management team of Scientific Industries during this conference call constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Except for the statements of historical fact, this

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.